Stay updated with breaking news from High Acuity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zacks Investment Research upgraded shares of Amedisys (NASDAQ:AMED – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. They currently have $180.00 price target on the health services provider’s stock. According to Zacks, “Amedisys ended the fourth quarter of 2021 with better-than-expected earnings […]
Van ECK Associates Corp grew its holdings in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 13.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 775 shares of the health services provider’s stock after purchasing an additional 93 shares during the period. Van ECK Associates Corp’s […]
Brokerages predict that Amedisys, Inc. (NASDAQ:AMED – Get Rating) will post sales of $557.81 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Amedisys’ earnings, with the highest sales estimate coming in at $569.00 million and the lowest estimate coming in at $548.85 million. Amedisys posted sales of $537.14 million during […]
State of Michigan Retirement System increased its holdings in Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 1.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,251 shares of the health services provider’s stock after acquiring an additional 100 shares […]
/PRNewswire/ -- "The organic order intake increased 6.4% in the fourth quarter following growth in all business areas and regions", says Mattias Perjos,...